Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

[1]  B. Sullenger,et al.  A high affinity, antidote‐controllable prothrombin and thrombin‐binding RNA aptamer inhibits thrombin generation and thrombin activity , 2012, Journal of thrombosis and haemostasis : JTH.

[2]  B. Sullenger,et al.  Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction* , 2012, The Journal of Biological Chemistry.

[3]  R. Becker,et al.  Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. , 2011, European heart journal.

[4]  P. Kamphuisen,et al.  Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents , 2011, Journal of thrombosis and haemostasis : JTH.

[5]  R. Becker,et al.  First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention , 2010, Circulation.

[6]  B. Sullenger,et al.  An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase* , 2009, The Journal of Biological Chemistry.

[7]  B. Sullenger,et al.  Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. , 2009, RNA.

[8]  Mark E. Davis,et al.  Development of universal antidotes to control aptamer activity , 2009, Nature Medicine.

[9]  R. Becker,et al.  Anticoagulant therapy during cardiopulmonary bypass , 2008, Journal of Thrombosis and Thrombolysis.

[10]  S. Steinhubl,et al.  Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.

[11]  R. Becker,et al.  A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.

[12]  J. Dieleman,et al.  Effects of cardiopulmonary bypass on neurocognitive performance and cytokine release in old and diabetic rats. , 2007, British journal of anaesthesia.

[13]  Alisa S Wolberg,et al.  Thrombin generation and fibrin clot structure. , 2007, Blood reviews.

[14]  B. Sullenger,et al.  Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. , 2007, Oligonucleotides.

[15]  G. Murphy,et al.  Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. , 2007, Journal of cardiothoracic and vascular anesthesia.

[16]  S. Steinhubl,et al.  First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.

[17]  B. Sullenger,et al.  A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  N. Mackman.  Tissue-Specific Hemostasis in Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. Olson,et al.  Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. , 2003, Biochemistry.

[20]  L. Cohn,et al.  Cardiac Surgery in the Adult , 2003 .

[21]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[22]  D. Monroe,et al.  Platelets and thrombin generation. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Carr,et al.  The heparin-protamine interaction. A review. , 1999, The Journal of cardiovascular surgery.

[24]  T. Warkentin,et al.  Heparin-Induced Thrombocytopenia: A Clinicopathologic Syndrome , 1999, Thrombosis and Haemostasis.

[25]  H. Philippou,et al.  Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass , 1994, The Lancet.

[26]  H. Philippou,et al.  Mechanisms of thrombin generation during surgery and cardiopulmonary bypass [see comments] , 1993 .

[27]  R. Colman,et al.  Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. , 1993, The Journal of thoracic and cardiovascular surgery.

[28]  R. Colman,et al.  Tissue factor is expressed on monocytes during simulated extracorporeal circulation. , 1993, Circulation research.

[29]  S. Olson,et al.  Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. , 1992, The Journal of biological chemistry.

[30]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[31]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[32]  R. Colman,et al.  Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. , 1989, Blood.

[33]  R. Jordan,et al.  Fractionation of low molecular weight heparin species and their interaction with antithrombin. , 1979, The Journal of biological chemistry.

[34]  M C Berenbaum,et al.  Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.

[35]  E. Davie,et al.  Waterfall Sequence for Intrinsic Blood Clotting , 1964, Science.

[36]  Macfarlane Rg,et al.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER , 1964 .

[37]  G. Fuhrer,et al.  Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. , 1986, Advances in experimental medicine and biology.

[38]  F. de Lange,et al.  Journal of Cardiothoracic Surgery Open Access a Novel Survival Model of Cardioplegic Arrest and Cardiopulmonary Bypass in Rats: a Methodology Paper , 2022 .